DEF: Alzamend Neuro Seeks Reverse Stock Split, New Equity Plan

Alzamend Neuro, Inc. announces its 2026 Annual Meeting of Stockholders to vote on key proposals including a reverse stock split, a new equity incentive plan, and director elections.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on April 17, 2026, at 12:00 p.m. ET.
• Key proposals include the election of seven directors, ratification of Haskell & White LLP as the independent registered public accounting firm, a non-binding advisory vote on named executive officer compensation, and approval of the 2025 Stock Incentive Plan.
• Stockholders will also vote on approving equity issuances to directors and executive officers to comply with Nasdaq listing rules, and an amendment to the Certificate of Incorporation to effect a reverse stock split by a ratio of not less than one-for-two and not more than one-for-ten.
• The proposed reverse stock split aims to increase the market price of the common stock to meet Nasdaq Capital Market listing requirements and attract a broader range of institutional investors.
• The 2025 Stock Incentive Plan, if approved, would authorize the issuance of a maximum of 1.6 million shares, potentially resulting in a 29.6% dilution to current stockholders.
• Specific equity issuances to directors and executive officers, totaling 1,210,000 shares, are proposed to re-incentivize them due to their prior options being 'underwater' as a result of the declining stock price, potentially causing an additional 24.1% dilution.
• The company reported a net loss of $5,105,084 for the fiscal year ended April 30, 2025, and $9,947,746 for the fiscal year ended April 30, 2024, with no revenue in either period.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment due to the severe decline in stock price necessitating a reverse split, consistent net losses with no revenue, and significant underperformance against peers, despite efforts to re-incentivize management.

Positives

• The Board is actively addressing Nasdaq listing requirements through a proposed reverse stock split, aiming to improve market perception and liquidity.
• The new 2025 Stock Incentive Plan and proposed equity issuances are designed to attract, retain, and motivate key executives and directors, aligning their interests with stockholders.
• The company maintains a Code of Business Conduct and Ethics and an insider trading policy, demonstrating a commitment to corporate governance.

Negatives

• The necessity of a reverse stock split indicates a significantly depressed stock price, having declined from approximately $13,972 at the IPO in June 2021 to $2.09 on the Record Date (February 25, 2026).
• Existing equity awards for directors and executive officers are 'underwater' or 'out-of-the-money,' rendering them ineffective as incentives, which the new issuances aim to rectify.
• The proposed 2025 Stock Incentive Plan and specific equity issuances could result in significant dilution to current stockholders (29.6% and 24.1% respectively, if fully issued).
• The company reported zero revenue and consistent net losses of $5,105,084 in fiscal year 2025 and $9,947,746 in fiscal year 2024.
• Past SEC settlement involving related parties (Hyperscale Data, Mr. Ault, and Mr. Horne) for alleged violations including material misstatements and failure to disclose related person transactions raises concerns about past governance practices.

Risks

• There is no assurance that the reverse stock split will result in the intended increase in market price or that the market price will not decrease in the future.
• The total market capitalization after a reverse stock split may be lower than before the split.
• The reverse stock split may result in some stockholders owning 'odd lots' (fewer than 100 shares), which can be more difficult to sell and incur higher brokerage commissions.
• Significant dilution to current stockholders is expected from the 2025 Stock Incentive Plan (29.6%) and the proposed equity issuances to directors and executive officers (24.1%).
• Failure to approve the equity issuances may lead to alternative compensation structures, such as cash retention bonuses, which could impact cash flow.
• The company's financial results, broader market conditions, and the market perception of its business could adversely affect the market price of its common stock.

Future Outlook

The company aims to improve its stock price and maintain Nasdaq listing through a proposed reverse stock split. It also seeks to re-incentivize management and directors with a new equity incentive plan and specific equity issuances, acknowledging past 'underwater' options. Future success hinges on these strategic moves and the performance of its drug candidates.

Management Comments

• We are using the latest technology in order to provide expanded access, improved communication and cost savings for our stockholders and the Company.
• The Board believes that the Equity Issuance is in the best interests of the Company and its stockholders, as it provides incentives to retain and motivate the Option Recipients without incurring the stock dilution that would result from stock awards or additional cash expenditures that would result from additional cash compensation.
• The Board continues to believe in value creation rather than value transfer and views the Equity Issuance as consistent with its approach of orienting long-term incentives toward stock options as the primary tool to minimize incremental dilution for stockholders, facilitate employee and director retention as the Company pursues its business strategies, restore the retention value of the Equity Issuance, and provide the Option Recipients with a more realistic incentive to drive stockholder value creation, thereby supporting the Company’s continued focus on stock price recovery and growth.
• In considering whether to implement the Equity Issuance, the Board determined that adverse changes in the market price of our Common Stock since the dates that the prior grants were made could materially interfere with our efforts to retain the services of the Option Recipients.

Industry Context

StockSavvy.ai notes that Alzamend Neuro operates in the highly volatile early and clinical stage biotechnology sector, which often experiences significant stock price fluctuations. The company's challenges with 'underwater' options and the need for a reverse stock split are not uncommon for companies in this industry facing market pressures and the long development cycles inherent in drug discovery.

Comparison to Industry Standards

• The company's peer group for Total Shareholder Return (TSR) includes Alector, Inc., Quince Therapeutics, Inc., Prothena Corporation plc, Anavex Life Sciences Corp., Voyager Therapeutics, Inc., Cassava Sciences, Inc., Denali Therapeutics, Inc., and LeonaBio, Inc.
• Alzamend Neuro's cumulative TSR for 2024 was $0.39, significantly underperforming its peer group's cumulative TSR of $42.26.
• For 2023, Alzamend Neuro's cumulative TSR was $4.65, compared to the peer group's $61.40.
• For 2022, Alzamend Neuro's cumulative TSR was $53.63, compared to the peer group's $91.79.
• The company's lack of revenue and consistent net losses are typical for early-stage biopharmaceutical companies, but the significant underperformance in TSR compared to its peers indicates specific challenges.

Management Changes

Corporate Governance

Legal Proceedings

• Hyperscale Data, Mr. Ault, and Mr. Horne settled with the SEC on August 15, 2023, for alleged violations including material misstatements, failure to disclose related person transactions, improper recording of consulting services, erroneous accounting of investments, and failure to maintain accounting and disclosure controls.
• Hyperscale Data paid a civil penalty of $700,000, Mr. Ault paid disgorgement of $85,504 and a civil penalty of $150,000, and Mr. Horne paid a civil penalty of $20,720 as part of the SEC settlement.
• The SEC ordered each of Hyperscale Data, Mr. Ault, and Mr. Horne to cease and desist from committing or causing future violations.
• Avalanche International Corp., where Mr. Horne served as CFO, filed for Chapter 7 bankruptcy on March 28, 2025, and was subsequently liquidated.

Related Party Transactions

• Milton C. Ault, III, the company's Founder and Vice Chairman, has significant influence over the company, directly and through his controlling interests in Hyperscale Data, Ault Lending, LLC, and ALSI.
• William B. Horne, the Chairman of the Board, is the Chief Executive Officer and a director of Hyperscale Data.
• Henry Nisser, the Executive Vice President, General Counsel, and a director, is the President, General Counsel, and a director of Hyperscale Data.
• The company's accounting and finance department uses shared office space within the Costa Mesa offices of Hyperscale Data.
• Past arrangements with Mr. Ault regarding board composition and a consulting agreement were in place, with the consulting agreement terminated upon his reappointment to the Board in January 2024.

Stakeholder Impact

• Shareholders face potential significant dilution from the proposed 2025 Stock Incentive Plan (29.6%) and specific equity issuances to directors and executive officers (24.1%).
• Shareholders may experience improved stock price and liquidity if the reverse stock split is successful, but also bear the risk of further price decline and the creation of 'odd lots'.
• Employees and directors are targeted for re-incentivization and retention through the new equity incentive plan and specific equity awards, addressing the issue of 'underwater' prior options.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on April 17, 2026, to vote on all proposals.
• If approved, implement the 2025 Stock Incentive Plan.
• If approved, effectuate the reverse stock split at a ratio determined by the Board (between 1-for-2 and 1-for-10) by April 16, 2027.
• If approved, issue equity awards to directors and executive officers.
• File a Current Report on Form 8-K with final voting results within four business days after the Annual Meeting.

Key Dates

Recommendation

The company's dire financial situation, marked by zero revenue, consistent net losses, and a stock price collapse necessitating a reverse split, indicates severe operational and market challenges. The proposed equity issuances, while intended to re-incentivize management, will cause substantial dilution to existing shareholders without a clear path to profitability. The significant underperformance against industry peers further underscores the high risk and poor prospects for current investors.

Keywords

Alzamend Neuro, ALZN, Proxy Statement, Reverse Stock Split, Equity Incentive Plan, Director Election, Executive Compensation, Nasdaq Listing, Biopharmaceutical, Corporate Governance, SEC Filing, Stock Dilution